Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation

Exclusion Criteria

• •Concomitant KRAS or NRAS and BRAF-V600 mutation or microsatellite instability high/deficient mismatch repair.
• •Prior treatment with a VEGF inhibitor, including bevacizumab or biosimilars.
• •Previous oxaliplatin treatment within 12 months prior to randomization, when arm open.
• •Known dihydropyrimidine dehydrogenase (DPD) deficiency.
• •Anticancer chemotherapy or biologic therapy administered within 28 days prior to the first dose of study drug.
• •Untreated or symptomatic brain metastasis.
• •Gastrointestinal (GI) disorder(s) that would significantly impede the absorption of an oral agent.
• •Unable or unwilling to swallow study drug.
• •Uncontrolled intercurrent illness.
• •Known hypersensitivity to fluoropyrimidine or leucovorin, irinotecan, or oxalipatin.
• •Abnormal glucuronidation of bilirubin; known Gilbert's syndrome.
• •Use of strong CYP3A4 or CYP2C19 inhibitors or strong CYP3A4 inducers.
• •QTc \>470